Docality.com Logo
 
Dr. James  Lamberti  Md image

Dr. James Lamberti Md

3289 Woodburn Road 350 Northern Virginia Pulmonary & Critical Care Assoc P
Annandale VA 22003
703 418-8616
Medical School: University Of Pennsylvania School Of Medicine - 1980
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: No
Participates In EHR: Yes
License #: 0101037926
NPI: 1538175823
Taxonomy Codes:
207RC0200X 207RP1001X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. James Lamberti is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99223 Description:Initial hospital care Average Price:$316.00 Average Price Allowed
By Medicare:
$213.81
HCPCS Code:94620 Description:Pulmonary stress test/simple Average Price:$161.87 Average Price Allowed
By Medicare:
$68.43
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$263.06 Average Price Allowed
By Medicare:
$179.61
HCPCS Code:94070 Description:Evaluation of wheezing Average Price:$94.00 Average Price Allowed
By Medicare:
$31.14
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$170.97 Average Price Allowed
By Medicare:
$116.94
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$162.35 Average Price Allowed
By Medicare:
$109.46
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$115.73 Average Price Allowed
By Medicare:
$76.36
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$115.65 Average Price Allowed
By Medicare:
$79.33
HCPCS Code:96401 Description:Chemo anti-neopl sq/im Average Price:$122.60 Average Price Allowed
By Medicare:
$86.51
HCPCS Code:94060 Description:Evaluation of wheezing Average Price:$47.00 Average Price Allowed
By Medicare:
$13.75
HCPCS Code:94060 Description:Evaluation of wheezing Average Price:$104.37 Average Price Allowed
By Medicare:
$71.63
HCPCS Code:94726 Description:Pulm funct tst plethysmograp Average Price:$95.00 Average Price Allowed
By Medicare:
$63.04
HCPCS Code:94729 Description:C02/membane diffuse capacity Average Price:$95.00 Average Price Allowed
By Medicare:
$63.11
HCPCS Code:94010 Description:Breathing capacity test Average Price:$71.53 Average Price Allowed
By Medicare:
$42.32
HCPCS Code:99231 Description:Subsequent hospital care Average Price:$62.41 Average Price Allowed
By Medicare:
$41.70
HCPCS Code:85610 Description:Prothrombin time Average Price:$26.00 Average Price Allowed
By Medicare:
$5.56
HCPCS Code:94762 Description:Measure blood oxygen level Average Price:$38.00 Average Price Allowed
By Medicare:
$18.33
HCPCS Code:71020 Description:Chest x-ray Average Price:$53.61 Average Price Allowed
By Medicare:
$35.95
HCPCS Code:94010 Description:Breathing capacity test Average Price:$26.00 Average Price Allowed
By Medicare:
$8.90
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$40.99 Average Price Allowed
By Medicare:
$28.07
HCPCS Code:36415 Description:Routine venipuncture Average Price:$12.00 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:Q2038 Description:Fluzone vacc, 3 yrs & >, im Average Price:$20.96 Average Price Allowed
By Medicare:
$13.29
HCPCS Code:Q2037 Description:Fluvirin vacc, 3 yrs & >, im Average Price:$21.00 Average Price Allowed
By Medicare:
$13.99
HCPCS Code:99406 Description:Behav chng smoking 3-10 min Average Price:$21.75 Average Price Allowed
By Medicare:
$15.07
HCPCS Code:J2357 Description:Omalizumab injection Average Price:$24.24 Average Price Allowed
By Medicare:
$22.84

HCPCS Code Definitions

94010
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
94010
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99231
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is stable, recovering or improving. Typically, 15 minutes are spent at the bedside and on the patient's hospital floor or unit.
G0008
Administration of influenza virus vaccine
Q2038
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
99406
Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
71020
Radiologic examination, chest, 2 views, frontal and lateral
Q2037
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
J2357
Injection, omalizumab, 5 mg
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
96401
Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
94726
Plethysmography for determination of lung volumes and, when performed, airway resistance
94620
Pulmonary stress testing; simple (eg, 6-minute walk test, prolonged exercise test for bronchospasm with pre- and post-spirometry and oximetry)
94762
Noninvasive ear or pulse oximetry for oxygen saturation; by continuous overnight monitoring (separate procedure)
94729
Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
94060
Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration
94070
Bronchospasm provocation evaluation, multiple spirometric determinations as in 94010, with administered agents (eg, antigen[s], cold air, methacholine)
94060
Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1356471676
Internal Medicine
2,104
1346257219
Pulmonary Disease
1,556
1629084918
Critical Care (Intensivists)
1,520
1003832023
Pulmonary Disease
1,384
1710993001
Pulmonary Disease
1,310
1194778027
Infectious Disease
1,027
1821014846
Pulmonary Disease
1,010
1750311130
Diagnostic Radiology
838
1548362791
Pulmonary Disease
787
1952392482
Cardiovascular Disease (Cardiology)
761
*These referrals represent the top 10 that Dr. Lamberti has made to other doctors

Publications

Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease. - Journal of cardiopulmonary rehabilitation and prevention
To characterize the cardiorespiratory response to exercise before and after aerobic exercise training in patients with interstitial lung disease.We performed a clinical study, examining 13 patients (New York Heart Association/World Health Organization Functional class II or III) before and after 10 weeks of supervised treadmill exercise walking, at 70% to 80% of heart rate reserve, 30 to 45 minutes per session, 3 times a week. Outcome variables included measures of cardiorespiratory function during a treadmill cardiopulmonary exercise test, with additional near infrared spectroscopy measurements of peripheral oxygen extraction and bioimpedance cardiography measurements of cardiac output. Six-minute walk test distance was also measured.All subjects participated in at least 24 of their 30 scheduled exercise sessions with no significant adverse events. After training, the mean 6-minute walk test distance increased by 52 ± 48 m (P = .001), peak treadmill cardiopulmonary exercise test time increased by 163 ± 130 s (P = .001), and time to achieve gas exchange threshold increased by 145 ± 37 s (P < .001). Despite a negligible increase in peak (Equation is included in full-text article.)o2 with no changes to cardiac output, the overall work rate/(Equation is included in full-text article.)o2 relationship was enhanced after training. Muscle O2 extraction increased by 16% (P = .049) after training.Clinically significant improvements in cardiorespiratory function were observed after aerobic exercise training in this group of subjects with interstitial lung disease. These improvements appear to have been mediated by increases in the peripheral extraction of O2 rather than changes in O2 delivery.
Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. - Chest
Pulmonary hypertension (PH) restricts the ability to engage in physical activity and decreases longevity. We examined the impact of aerobic exercise training on function and quality of life in patients with World Health Organization group 1 PH.Patients were randomized to a 10-week education only (EDU) or education/exercise combined (EXE) group. The exercise program consisted of 24-30 sessions of treadmill walking for 30-45 min per session at 70% to 80% of heart rate reserve. Outcome variables included changes in 6-min walk test (6MWT) distance, time to exercise intolerance, peak work rate (WR) from a cardiopulmonary treadmill test, and quality-of-life measures, including the Short Form Health Survey, version 2 (SF-36v2) and Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).Data are presented as mean SD. Twenty-three women (age, 54 11 years; BMI, 31 7 kg/m 2 ) were randomized to the EDU (n 5 13) or EXE (n 5 10) groups. Following 10 weeks of intervention, patients in the EXE group demonstrated an improvement in 6MWT distance (56 45 m; P 5 .002), increased time to exercise intolerance (1.9 1.3 min; P 5 .001), and peak WR (26 23 W; P 5 .004). Additionally, the EXE group scored significantly ( P , .050) better on six of the eight scales on SF-36v2, and fi ve of the six scales on CAMPHOR. In contrast, no significant improvement was observed for any of the outcome measures following EDU. No adverse events were noted in either group.Ten weeks of brisk treadmill walking improved 6MWT distance, cardiorespiratory function, and patient-reported quality of life in female patients with group 1 PH.
The use of spirometry testing prior to cardiac surgery may impact the Society of Thoracic Surgeons risk prediction score: a prospective study in a cohort of patients at high risk for chronic lung disease. - The Journal of thoracic and cardiovascular surgery
Chronic lung disease is a significant comorbidity in patients undergoing cardiac surgery. Chronic lung disease is currently being classified and reported to the Society of Thoracic Surgeons database by using either clinical interview or spirometric testing. We sought to compare the chronic lung disease classification captured by the 2 methods.We performed a prospectively designed study in which patients presenting for cardiac surgery, excluding emergent patients, were screened for a history of asthma, a history of 10 or more pack-years of smoking, a persistent cough, and the use of oxygen. Each selected patient underwent spirometry. The presence and severity of chronic lung disease was coded per Society of Thoracic Surgeons guidelines by using the 2 methods of clinical report and spirometric results. The chronic lung disease classifications were compared, and differences were determined by using concordance and discordance rates. The results were then used to construct Society of Thoracic Surgeons-predicted risk models.The discordant rate was 39.1%, with underestimation of the severity of chronic lung disease in 94% of misclassified patients. This affected the Society of Thoracic Surgeons-predicted risk models for prolonged ventilation, morbidity/mortality, and mortality by increasing the predicted risk when spirometry was used for morbidity/mortality by an average of 1.5 +/- 1.2 percentage points (P < .001) and prolonged ventilation time by an average of 1.3 +/- 1.4 percentage points (P < .001).The use of patient history for symptoms, medication, and/or oxygen use as the only method to determine chronic lung disease for this subgroup of patients led to underreporting of chronic lung disease and underestimation of the risk for adverse outcomes. Therefore data submission to the Society of Thoracic Surgeons database should be designed to capture and correct for potential bias in the definition of chronic lung disease because the rate of spirometry in different centers in defining chronic lung disease is not regulated.Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Late stage (III and IV) non-small cell cancer of the lung: results of surgical resection at Inova Fairfax Hospital. - Southern medical journal
One hundred forty-two patients underwent surgery and related treatment for advanced stage (III, IV) non-small cell cancer of the lung. One hundred seventeen patients underwent up-front surgery, with a hospital mortality rate of 1.7% (2/117). Kaplan-Meier 5-year survival in this group was 31% (+/- 5). Twenty-five patients underwent neoadjuvant therapy followed by surgical resection, with respective rates of hospital mortality, complete pathologic response, and major pathologic response of 0%, 16%, and 64%. Kaplan-Meier 5-year survival in this latter group was 34% (+/- 11). Of the 16 patients undergoing neoadjuvant therapy who had complete pathologic response or significant downstaging from stage III disease, Kaplan-Meier 5-year survival was 61% (+/- 15). Three clinical observations of interest emerged regarding survival. First, in those patients with postresection FEV1 < 1.0 L, hospital mortality rate was 20%, and there were no 5-year survivors (P < 0.0001). Second, where neoadjuvant therapy was associated with complete pathologic response or significant downstaging of disease, there was a trend for improved survival in the downstaged group, but it did not reach statistical significance (P = 0.14). Third, adjuvant therapy was associated with improved 5-year survival (P = 0.03), particularly for combination chemotherapy and radiotherapy (P = 0.02).
Mediastinal staging of non-small cell lung carcinoma using computed and positron-emission tomography. - Southern medical journal
We evaluated the accuracy of computed tomography (CT) and positron-emission tomography (PET) in the mediastinal staging of non-small cell lung cancer.Between May 14, 1999, and November 28, 2000, computerized tomography (CT) and positron-emission tomography (PET) were used to clinically stage 94 consecutive patients with non-small cell carcinoma of the lung (NSCCL). All patients underwent subsequent surgical staging with mediastinoscopy, anterior mediastinotomy, and/or thoracotomy with mediastinal lymphadenectomy.Overall accuracy was the same for both procedures. False-negative results occurred 3 times more often with CT; false-positive results occurred twice as often with PET. Sensitivity and specificity were 64% and 94%, respectively, for CT, versus 88% and 86%, respectively, for PET. Positive and negative predictive values were 80% and 88%, respectively, for CT, versus 71% and 95%, respectively, for PET.In addition to routine use of CT, PET seems to achieve high negative predictive value in the evaluation of mediastinal disease; PET seems particularly helpful in assessing absence of tumor in bulky nodes after neoadjuvant chemotherapy and/or radiotherapy.

Map & Directions

3289 Woodburn Road 350 Northern Virginia Pulmonary & Critical Care Assoc P Annandale, VA 22003
View Directions In Google Maps

Nearby Doctors

7617 Little River Turnpike Suite 600
Annandale, VA 22003
703 565-5680
7004 Little River Tpke Suite # C
Annandale, VA 22003
703 160-0303
4540A John Marr Dr
Annandale, VA 22003
703 333-3016
3289 Woodburn Rd Suite 060
Annandale, VA 22003
703 985-5171
7700 Little River Tpke Ste 101
Annandale, VA 22003
703 587-7070
7601 Little River Tpke Suite 100
Annandale, VA 22003
571 255-5523
3289 Woodburn Rd Suite # 200
Annandale, VA 22003
703 607-7900
7815 Rebel Dr
Annandale, VA 22003
703 988-8881
Northern Virginia Pulmonary & Critical Care Assoc. Pc 3289 Woodburn Road, 350
Annandale, VA 22003
703 418-8616
3289 Woodburn Rd #060
Annandale, VA 22003
703 980-0666